These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 29952297)

  • 1. Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study.
    Griffiths CE; Stein Gold L; Cambazard F; Kalb RE; Lowson D; Møller A; Paul C
    Eur J Dermatol; 2018 Jun; 28(3):356-363. PubMed ID: 29952297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients With Psoriasis Vulgaris: Results from the Randomized PSO-FAST Study.
    Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Moller A; Osterdal ML; Stein Gold L
    J Drugs Dermatol; 2016 Aug; 15(8):981-7. PubMed ID: 27537999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study.
    Paul C; Leonardi C; Menter A; Reich K; Gold LS; Warren RB; Møller A; Lebwohl M
    Am J Clin Dermatol; 2017 Jun; 18(3):405-411. PubMed ID: 28236223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam.
    Jalili A; Lebwohl M; Stein Gold L; Andersen SB; Jensen KL; Pink AE; Segaert S; Berg P; Calzavara-Pinton PG; de la Cueva Dobao P; Thaçi D
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):709-717. PubMed ID: 30520168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study.
    Paul C; Stein Gold L; Cambazard F; Kalb RE; Lowson D; Bang B; Griffiths CE
    J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):119-126. PubMed ID: 27531752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).
    Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Olesen M; Østerdal ML; Stein Gold L
    J Drugs Dermatol; 2015 Dec; 14(12):1468-77. PubMed ID: 26659941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study.
    Koo J; Tyring S; Werschler WP; Bruce S; Olesen M; Villumsen J; Bagel J
    J Dermatolog Treat; 2016; 27(2):120-7. PubMed ID: 26444907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease.
    Pink AE; Jalili A; Berg P; Calzavara-Pinton PG; de la Cueva Dobao P; Thaçi D; Torpet M; Jensen KL; Segaert S
    J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1116-1123. PubMed ID: 30916417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study.
    Lambert J; Hol CW; Vink J
    J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2349-55. PubMed ID: 26337069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled Studies.
    Stein Gold L; Lebwohl M; Menter A; Villumsen J; Rosen M; Koo J
    J Drugs Dermatol; 2016 Aug; 15(8):951-7. PubMed ID: 27537995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris.
    Queille-Roussel C; Olesen M; Villumsen J; Lacour JP
    Clin Drug Investig; 2015 Apr; 35(4):239-45. PubMed ID: 25708531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Compared with Betamethasone 17-Valerate-Medicated Plaster for the Treatment of Psoriasis.
    Queille-Roussel C; Rosen M; Clonier F; Nørremark K; Lacour JP
    Clin Drug Investig; 2017 Apr; 37(4):355-361. PubMed ID: 27995521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam With Apremilast for Moderate Plaque Psoriasis.
    Kircik LH; Schlesinger TE; Tanghetti E
    J Drugs Dermatol; 2020 Sep; 19(9):874-880. PubMed ID: 33026749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A post-hoc analysis of PSO-LONG.
    Jalili A; Calzavara-Pinton P; Kircik L; Lons-Danic D; Pink A; Tyring S; de la Cueva P; Gooderham M; Segaert S; Nyholm N; Thoning H; Petersen B; Thaçi D
    J Eur Acad Dermatol Venereol; 2022 Jan; 36(1):60-67. PubMed ID: 34543474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psoriasis and skin pain: real-life effectiveness of calcipotriol plus betamethasone dipropionate in aerosol foam formulation.
    Gallo L; Megna M; Cirillo T; Caterino P; Lodi G; Mozzillo R; Dente V; Balato A
    J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1312-1315. PubMed ID: 30767288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.
    Bewley AP; Shear NH; Calzavara-Pinton PG; Hansen JB; Nyeland ME; Signorovitch J
    J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1107-1115. PubMed ID: 30472749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Cost-utility Analysis of Calcipotriol/Betamethasone Dipropionate Aerosol Foam versus Ointment for the Topical Treatment of Psoriasis Vulgaris in Sweden.
    Duvetorp A; Levin LÅ; Engerstedt Mattsson E; Ryttig L
    Acta Derm Venereol; 2019 Apr; 99(4):393-399. PubMed ID: 30628631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States.
    Wu JJ; Veverka KA; Lu M; Armstrong AW
    J Dermatolog Treat; 2019 Aug; 30(5):454-460. PubMed ID: 30307343
    [No Abstract]   [Full Text] [Related]  

  • 19. A Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy.
    Bagel J; Zapata J; Nelson E
    J Drugs Dermatol; 2018 Aug; 17(8):845-850. PubMed ID: 30124723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile.
    Paul C; Bang B; Lebwohl M
    Expert Opin Pharmacother; 2017 Jan; 18(1):115-121. PubMed ID: 27936972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.